Related Experiment Video

Updated: Nov 30, 2025

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.2K

Trabectedin for the therapy of ovarian cancer

G Evangelisti1,2, F Barra1,3, G D'Alessandro1,2

  • 1Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Drugs of Today (Barcelona, Spain : 1998)
|November 13, 2020
PubMed

Insights

Trabectedin, a marine-derived antitumor drug, shows efficacy and safety in treating ovarian cancer (OC) and other solid tumors. It offers benefits in platinum-sensitive recurrent OC, including BRCA-mutated cases, and extends time to next chemotherapy.

Area of Science:

  • Marine pharmacology
  • Oncology
  • Drug development

Background:

  • Trabectedin is a marine-derived antitumor agent with demonstrated cytotoxic activity and a favorable safety profile.
  • It has been explored for various solid malignancies, including ovarian cancer (OC), breast cancer, and soft-tissue sarcoma.

Purpose of the Study:

  • To review the efficacy and safety of trabectedin in treating ovarian cancer.
  • To highlight its role in platinum-sensitive recurrent OC and its benefits in specific patient subgroups.
  • To discuss its potential in combination with targeted therapies.

Main Methods:

  • Review of pivotal clinical trial data (e.g., OVA-301).
  • Analysis of subgroup data for platinum-sensitive and BRCA-mutated OC patients.
  • Examination of studies on time to subsequent chemotherapy and combination therapies.

Main Results:

  • European Medicines Agency (EMA) approval in 2009 for platinum-sensitive recurrent OC in combination therapy.
  • Demonstrated benefit in partially platinum-sensitive and BRCA-mutated OC subgroups.
  • Extended the interval to the next line of chemotherapy.

Conclusions:

  • Trabectedin is an established treatment option for specific ovarian cancer indications.
  • Its efficacy in platinum-sensitive recurrent OC, including specific subgroups, is well-documented.
  • Ongoing research explores novel combinations of trabectedin with targeted therapies for enhanced antitumor action.
Keywords:
BRCA-mutated ovarian cancerDNA-damaging drugsHomologous recombinationIL-6 production inhibitorsOvarian cancer therapyTrabectedinTumor microenviroment

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
476